While most crypto CEOs are busy navigating market volatility,Brian Armstrong
One moment he’s rallying for stablecoin legislation on Capitol Hill, the next he’s funding research to literally reverse the aging process.
Here’s the latest on Armstrong, for all Coinbase enthusiasts out there!
Armstrong’s biotech venture NewLimit, co-founded with former GV partner Blake Byers and stem cell scientist Jacob Kimmel, just closed a $130 million Series B round. The startup, now valued at $810 million, is developing therapies that aim to restore youthful function to aging cells through epigenetic reprogramming.
Early results are promising. The team has identified three prototype medicines targeting liver cells – improving their fat and alcohol processing capabilities in lab tests.
While human trials are still years away, NewLimit is expanding into immune system research, with Armstrong citing the urgency of fighting what he calls the “largest source of human tragedy” – aging.
The round was led by Kleiner Perkins and backed by a powerful lineup of investors including Founders Fund, Elad Gil, Patrick Collison, and Garry Tan.
Armstrong isn’t alone in this mission. He joins the ranks of tech elites like Jeff Bezos, Larry Ellison, and Vitalik Buterin – all pouring hundreds of millions into anti-aging research. But Armstrong’s approach is distinctive: part-scientist, part-operator, and always ten steps ahead.
The Coinbase CEO hasn’t loosened his grip on crypto advocacy. Just yesterday on X, he called on the U.S. Senate to move forward on the GENIUS Act – a stablecoin regulation bill that could finally bring clear rules to the space.
The GENIUS Act would introduce a federal licensing regime, enforce reserve requirements for issuers, and create a dual regulatory model – splitting oversight between federal and state levels depending on issuer size.
The push comes just as the Treasury predicts stablecoins could surge from $230B to $2T by 2028, presenting both an opportunity and a risk to traditional banking systems.
Here’s how we see it: Brian Armstrong is betting on the future, and he’s doing it from all sides.
NewLimit is a biotech startup co-founded by Brian Armstrong to reverse aging via epigenetic cell reprogramming.
The GENIUS Act proposes federal and state oversight, reserve rules, and licenses to regulate stablecoin issuers.
Solana (SOL) saw a massive jump in open interest during July, rising by over 370%,…
Cardano (ADA) is showing signs of weakness as its long/short ratio drops, signaling a surge…
With XRP struggling to hold key support and whales quietly loading up, all eyes are…
Ozak AI is catching serious attention as it pushes deeper into its 4th presale stage.…
Michael Saylor is doubling down on Bitcoin again. In a recent CNBC interview, he hinted…
Early investors in Shiba Inu and Pepe Coin saw life-changing returns. Now, ChatGPT and other…